Table S7 Summary of findings table for outcome indicators

Patient or population: patients with plaque psoriasis and psoriatic arthritis
Intervention: Tofacitinib
Comparison: Placebo

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)
	Assumed risk **Placebo**	Corresponding risk **Tofacitinib**			
PASI 75	Study population		**RR 5.21** (4.09 to 6.65)	6401 (7 studies)	⊕⊕⊕⊖ **moderate**
	88 per 1000	460 per 1000 (361 to 587)			
	Moderate				
	83 per 1000	432 per 1000 (339 to 552)			
PASI 90	Study population		**RR 12.63** (8.81 to 18.11)	3539 (5 studies)	⊕⊕⊕⊕ **high**
	25 per 1000	321 per 1000 (224 to 460)			
	Moderate				
	9 per 1000	114 per 1000 (79 to 163)			
PGA 0/1	Study population		**RR 4.7** (4.12 to 5.36)	5752 (5 studies)	⊕⊕⊕⊕ **high**
	111 per 1000	521 per 1000 (457 to 595)			
	Moderate				
	100 per 1000	470 per 1000 (412 to 536)			
Nasopharyngitis	Study population		**RR 1.07** (0.86 to 1.34)	4504 (7 studies)	⊕⊕⊕⊖ **moderate**
	63 per 1000	68 per 1000 (54 to 85)			
	Moderate				
	56 per 1000	60 per 1000 (48 to 75)			
URTI	Study population		**RR 1.64** (1.2 to 2.25)	4504 (7 studies)	⊕⊕⊕⊕ **high**
	33 per 1000	54 per 1000 (40 to 75)			
	Moderate				
	34 per 1000	56 per 1000 (41 to 77)			
Hypercholesterolemia	Study population		**RR 2.75** (1.67 to 4.53)	3459 (4 studies)	⊕⊕⊕⊕ **high**
	16 per 1000	44 per 1000 (26 to 72)			
	Moderate				
	20 per 1000	55 per 1000 (33 to 91)			
CPK elevation	Study population		**RR 2.07** (1.28 to 3.34)	3526 (4 studies)	⊕⊕⊕⊕ **high**
	17 per 1000	35 per 1000 (22 to 57)			
	Moderate				

		16 per 1000	**33 per 1000** (20 to 53)		
Headache	**Study population**			**RR 1.69** (1.2 to 2.4)	3277 (5 studies)	⊕⊕⊕⊕ **high**
	35 per 1000	**59 per 1000** (42 to 83)			
	Moderate				
	31 per 1000	**52 per 1000** (37 to 74)			

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.